Hong Kong stocks fluctuate | Novartis (09969.HK) rose more than 3% as obinutuzumab was approved in China for first-line treatment of CLL/SLL.

According to the Wise Financial APP, Nuocheng Jianhua (09969.HK) rose more than 3%, as of the time of publication, it increased by 1.34%, closing at 9.85 Hong Kong dollars, with a turnover of 1195.82 million Hong Kong dollars.